Ionis Pharmaceuticals (IONS) Retained Earnings (2009 - 2026)

Ionis Pharmaceuticals' Retained Earnings history runs 18 years deep, the most recent figure standing at -$31.0 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 7.16% year-over-year to -$31.0 million in Q1 2026; TTM through Mar 2026 was -$31.0 million, a 7.16% decrease from a year earlier, with the FY2025 full-year figure at -$25.3 million, up 98.88% from the prior year.
• Retained Earnings declined to -$31.0 million in Q1 2026 per IONS's latest filing, from -$25.3 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$25.3 million in Q4 2025 and bottomed at -$2.3 billion in Q2 2025.
• The 5-year median for Retained Earnings is -$1.3 billion (2022), against an average of -$976.6 million.
• Biggest YoY gain for Retained Earnings was 98.88% in 2025; the steepest drop was 6425.04% in 2025.
• Year by year, Retained Earnings stood at -$57.5 million in 2022, then slumped by 3024.41% to -$1.8 billion in 2023, then declined by 25.27% to -$2.2 billion in 2024, then soared by 98.88% to -$25.3 million in 2025, then retreated by 22.71% to -$31.0 million in 2026.
• Per Business Quant, the three latest IONS Retained Earnings figures stand at -$31.0 million (Q1 2026), -$25.3 million (Q4 2025), and -$26.0 million (Q3 2025).